ERBB2 and neoplasm: which binds to subdomain IV of HER-2 ECD, pertuzumab binds to subdomain II of the HER-2 ECD and inhibits heterodimerization between (1) HER-2 and HER-1 and (2) HER-3 and HER-4, thereby blocking downstream tumor signaling (11).